PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (January 2026)
32 slides from PetVivo's investor presentation, Jan 22, 2026
Slide 1: Investor Presentation January 2026
Investor Presentation January 2026 PETV (OTCQX)
Slide 2: Forward-Looking Statements
Forward-Looking Statements PETYIVO This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities leanne which statements ale gulifzes to substantial risks and uncertainties that could cause actual results to differ materially
Slide 3: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Commercial e Product Portf Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechanics for the managem
Slide 4: Osteoarthritis: a common affliction of the joints
Osteoarthritis: acommon affliction of the joints e Affects approximately 34 million adult dogs and 1 million horses* e@ Causes pain and inflammation from degenerated cartilage of stressed joints e Lameness worsens with time from ongoing loss of cartilage and the presence of inflammation in the joint
Slide 5: Viscosupplementation
Viscosupplementation A strong hydrated biomaterial that facilitates enhanced Lubrication and joint-cushioning properties. fo) Micro-scaffolds Over time, micro-scaffolds adhere to and integrate with the existing synovial membrane. @ Collagen-Elastin Microparticles Porous, spongy particles absorb and
Slide 6: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng® with OsteoCushion® Technology e Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function © Similar components/function found in natural cartilage (i.e. collagen, elastin and he
Slide 7: Spryng with OsteoCushion Technology
Spryng® with OsteoCushion® Technology e Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms e Purified natural components self-assemble to form an insoluble, hydrated matrix e Protein source bovine tissues (i.e. medical grade collagen and elastin)
Slide 8: Spryng Mechanism of Action
Spryng® Mechanism of Action e Ananimal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain, and further loss of cartilage. e Spryng reinforces synovial membrane function, without
Slide 9: Spryng Canine Success: Cooper
Spryng® Canine Success: Cooper Treatment e@ On January 14, 2025, Cooper received Spryng® with OsteoCushion™ Technology injections in both elbows. Condition 7-year-old mixed-breed dog. Diagnosed with severe arthritis in both elbows in March 2024. After injection, the elbows were moved through a range
Slide 10: Spryng Equine Success
Spryng® Equine Success: History 16-year-old Saddlebred mare. Fergie shows as a Saddlebred monthly and ridden 5-6 days per week. However, due to apparent discomfort, she had become choppy, awkward and sometimes hesitant to change gaits or directions. Hard for her to stay ina good frame for riding, es
Slide 11: Spryng Competitive Distinctions
Spryng® Competitive Distinctions e@ Outcomes address affliction/not just symptoms e Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction Price/Cost advantage Derived from all natural materials Ease of application Vet clinic exclu
Slide 12: Spryng Product Category Comparison
Spryng® Product Category Comparison Features Spryng® Injections per Year Benefits Last up to 42 Months or More Bioscaffold From Naturally-Derived Components No Synthetic or Radioactive Material Research Supports Joints Health Benefits No Drug Interactions & No Systemic Effects (Medical Device) All S
Slide 13: Spryng Tolerance Studies
Spryng® Tolerance Studies Bs Feline Tolerance Purpose: Assess tolerance of Spryng™ administration in cats. Design: 10 healthy female cats received intra- articular injection with saline or Spryng in contralateral shoulder, hip, elbow, and stifle joints in a randomized sequence. Two-week washout peri
Slide 14: Spryng Clinical Studies
Spryng® Clinical Studies CanineHipOA CASE ETHOS spSSUQRADOANIMAL VETERINARY HEALTH Purpose: Study the effects of Collagen-Elastin Hydrogel Microparticles (Spryng) on pain & function secondary to hip osteoarthritis in dogs. Investigators: Colorado Animal Specialty & Emergency with Ethos Veterinary He
Slide 15: New Spryng Clinical Trials
New Spryng® Clinical Trials Underway or Recently Completed, Awaiting Publication a Canine Study at Colorado State University Principal investigators: Felix Duerr, DVM, MS, Dr. med. vet., CCRT, DACVS-SA, DECVS, DACVSSMR Pilot study design: Pilot study evaluating intra-articular injection of a hydroph
Slide 16: PrecisePRP: No Centrifuge Required
P recise Pp R Pp Me No Centrifuge Required Freeze-dried, pooled, leukoreduced, RBC removed, allogeneic. ERS ° No Blood Draw Sterility, endotoxin and mycoplasma evaluated every time. Consistent Dosing Platelet Derived Growth Factor (PDGF-BB) measured in every batch. Total platelet dose per vial equal
Slide 17: What is Platelet-Rich Plasma (PRP)?
What is Platelet-Rich Plasma (PRP)? e The most common regenerative therapy utilized in veterinary medicine. e Concentrated preparation of platelets and plasma. e First published use in the 1970s as an intralesional and fracture repair product in horses and dogs. e Benefits of PRP o Many publications
Slide 18: Common Uses of Platelet-Rich Plasma in Veterinary Medicine
Common Uses of Platelet-Rich Plasma in Veterinary Medicine In Conjunction with Stem Cell Therapy Wound Healing Post Surgical Healing Ophthalmic Uses e Corneal Ulceration e Keratoconjunctivitis Sicca e Descemetocele Dental and Oral Surgical Procedures Musculoskeletal Disease/Injury e Osteoarthritis e
Slide 19: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities e Spryng® product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 e Initial batch sizes of approx. 500 syringes; planning to increase to batches of 5,000+ syringes per month. e Current production facility annual capacity is approx
Slide 20: Comprehensive IP Portfolio US and Foreign Issued Patents
Comprehensive IP Portfolio 12 US and Foreign Issued Patents Broad Claim Language - “Comprising” Transitions d 6 Detailed Proprietary Trade Secrets Our Patents & Trade Secrets Protect: Protein & Carbohydrate Based Thermoplastics Biomaterials of Many Compositions Medical, Drug Delivery & Combination P
Slide 21: Market Overview
Sources: American Pet Products Assoc.; North M a r ket Ove av i ew American Pet Health Insurance Association, American Horse Council, LendEDU Companion Animal/Veterinarian * Agricultural and professional equine markets not included e US Pet Spend increased from $152B in 2024 to $157B in 2025 e Veter
Slide 22: Pet Product Pipeline
Pet Prod uct Pi pel I ne No FDA Review or Clearance Required for FDA clearance not required Commercialization of Veterinary Medical Devices Product 4 ; 5 3 Commercial —— VD-01 Osteoarthritis Canine (Spryng®) 932021 9 VD-02 Osteoarthritis Equine (Spryng®) Q3 2021 VD-08 Osteoarthritis Canine (SmartSpr
Slide 23: Distribution Partners
Distribution Partners MWI Animal Health* cencora MWI Animal Health MWI - PetVivo Distribution Services Agreement Terms: e Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party e Designated distributor for PetVivo’s veterinary medical device, Spryng
Slide 24: Wholesale Partners
Wholesale Partners SNEDCO Animal Health Vedco Vedco - Wholesaler Engagement: e Wholesaler relationship to purchase product from PetVivo and sell it to national distributors for subsequent sale to U.S. vets e Designated wholesaler for PetVivo’s veterinary medical device, Spryng® with OsteoCusion® Tec
Slide 25: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Exclusive White Label License Relationship: e Exclusive white label license agreement between PetVivo and Digital Landia for the AgenticPet™ Al B2B platform. e PetVivo holds exclusive commercialization and deployment rights in veterinary ma
Slide 26: Digital Landia, LLC (Agentic Pet): Development Status
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Current Development Status and Third Party Validation e Core multi-agent architecture completed and operating in controlled beta environments. e Secure API integrations and modular deployment framework finalized for B2B partners. e Ongoing
Slide 27: PetVivo Strategic Partners
PetVivo Strategic Partners PiezoBioMembrane, Inc. (“PBM”) and Veterinary Growth Partners (“VGP”) PBM (Functional Biomaterials) Relationship — Master Services Agreement (Joint R&D): Collaboration on the research and development of a novel piezo biomaterials for therapeutic applications (e.g Smart-Spr
Slide 28: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience Josh Wilhelm John Lai Garry Lowenthal John F. Dolan April Boyce General Counsel VP of Sales & Marketing VP of Operations & R&D AA, HEALTH CEO, President & Director - pwe A tRAusT Deloitte. Fredeitson a> etn rikso
Slide 29: Strong Independent Board of Directors and Advisors
Strong Independent Board of Directors and Advisors Advisors * Dr. Tracy Turner, DVM, MS, Dipl. ACVS, Dipl. ACSMR, Amer. Academy Thermology, AAEP Board * Dr. Sherman Cannap, DVM, MS, CCRT, DACVS-SA, DACVSMR, Cannap Sports Medicine, Orthobiologic Innovations * Dr. Debra Cannap, DVM, CCRT, CVA, DACVSMR
Slide 30: Growth Drivers
Growth Drivers Sales Growth & Expansion e US Direct Veterinary Sales Force e 100% US veterinary market coverage via established distributor network. e International expansion; UK/MX (2025) CA (Q2 2026); EU expected CY2026. @ Momentum and growth in clinic adoption and use cases delivering ~ 17% incre
Slide 31: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary care and product sales market with ~ 6% historical CAGR (2020-2024)* Commercialized Regenerative Product Portfolio Spryng®, with OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechan
Slide 32: John Lai, Chief Executive Officer
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 Spryng® with OsteoCushion™ Technology and PrecisePRP™ are exclusively sold and distributed by PetVivo Animal Health. Veterinary Use Only - Federal law restricts this device to use by or on the order of a licensed veterinarian. 844-Pet-
PetVivo Holdings — Investor Presentation (January 2026) on 6ix